Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
LabCorp Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.
LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds
by Urmimala Biswas
LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
by Zacks Equity Research
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View
by Zacks Equity Research
LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.
LabCorp (LH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 2.11% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 24 Earnings Roster: BAX, CERN & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
What's in the Offing for LabCorp's (LH) Earnings in Q3?
by Zacks Equity Research
LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.
LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
LabCorp (LH) Names Two Leaders for Major Business Wings
by Zacks Equity Research
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
LabCorp to Expand Hematology Suite With Sysmex America Deal
by Zacks Equity Research
LabCorp (LH) will get to use Sysmex' advanced XN-9100 system, which is a scalable, modular automation system.
LabCorp's Covance Launches Laboratory Data Management Service
by Zacks Equity Research
LabCorp (LH) expands service portfolio through Covance's data management portal.
LabCorp (LH) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Value Investors Pick Laboratory Corporation (LH) Stock?
by Zacks Equity Research
Let's see if Laboratory Corporation (LH) stock is a good choice for value-oriented investors right now from multiple angles.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
LabCorp (LH) Tops Q2 Earnings Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 1.03% and -0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
by Zacks Equity Research
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
LabCorp Diagnostics Shows Robust Growth Amid Price Declines
by Zacks Equity Research
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor
by Zacks Equity Research
Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor
Robust Sales Growth Makes These 5 Stocks Worth Buying Now
by Swayta Shah
Sales growth provides investors an insight into product demand and pricing power.
LH vs. XRAY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. XRAY: Which Stock Is the Better Value Option?